Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab and chemotherapy in pancreatic cancer liver metastasis
NCT06531278Phase 2Recruiting
- Start
- Jul 2024
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in pancreatic ductal adenocarcinoma (PDAC). Primary endpoint: Objective Response Rate up to 1 year. Started Jul 2024; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06531278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06531278.